{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:55:05Z","timestamp":1793152505359,"version":"4.5.0"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"\n Importance<\/jats:title>\n Obesity is a chronic condition with negative consequences for patients, the health care system, and society. The most effective treatment of class II and III obesity is metabolic bariatric surgery (MBS), which is usually considered a last resort. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have recently shown promising results.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare weight loss and ongoing costs associated with MBS and GLP-1 RAs in the US.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study used data from the Highmark Health insurance claims database and the Allegheny Health Network electronic medical record in the US. Participants were patients with class II or III obesity treated with either MBS or GLP-1 RAs who were enrolled in Highmark insurance for at least 6 months prior to index treatment and had follow-up data available for at least 12 months. Using propensity score weighting, the populations were adjusted for differences in baseline spending, health care utilization, age, sex, comorbidities, and smoking status. Data were analyzed from July 2024 to July 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n MBS (sleeve gastrectomy or gastric bypass) vs GLP-1 RAs (dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, or tirzepatide).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The main outcomes were total weight loss and monthly ongoing costs (pharmacy, medical, and surgery costs) at baseline and over 2 years after index treatment. Mean adjusted costs were calculated using a linear mixed-effects model.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Analyses included 30\u202f458 patients (mean [SD] age, 50 [11] years; 20\u202f118 [66.1%] female), with 14\u202f101 undergoing MBS (mean [SD] follow-up, 34 [16] months) and 16\u202f357 receiving GLP-1 RAs (mean [SD] follow-up, 32 [17] months). After propensity score weighting, baseline characteristics were comparable. The mean (SE) total costs over 2 years were $63\u202f483 ($1563) for GLP-1 RAs and $51\u202f794 ($1724) for MBS (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). The main driver of this difference was higher sustained pharmacy costs in the GLP-1 RA group throughout year 2 of follow-up. Comparing weight loss data of 257 patients using GLP-1 RAs and 1291 patients who underwent MBS, total weight loss was greater for the MBS group (mean [SE], 28.3% [0.3%]) than the GLP-1 RA group (mean [SE], 10.3% [0.5%]) (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n These findings suggest that MBS was associated with more weight loss at lower ongoing costs compared with GLP-1 RAs in class II and III obesity. Further study is needed to determine if MBS should still be considered the last resort in treating obesity.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamasurg.2025.3590","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:00:22Z","timestamp":1758121222000},"page":"1232","source":"Crossref","is-referenced-by-count":94,"title":["Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists"],"prefix":"10.1001","volume":"160","author":[{"given":"Tyson S.","family":"Barrett","sequence":"first","affiliation":[{"name":"Highmark Health, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane O.","family":"Hafermann","sequence":"additional","affiliation":[{"name":"Coreva Scientific, Koenigswinter, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Richards","sequence":"additional","affiliation":[{"name":"Highmark Health, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"LeJeune","sequence":"additional","affiliation":[{"name":"Highmark Health, Pittsburgh, Pennsylvania"},{"name":"Allegheny Health Network, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George M.","family":"Eid","sequence":"additional","affiliation":[{"name":"Allegheny Health Network, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10431","key":"soi250059r1","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.","volume":"403","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"soi250059r2","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis.","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"soi250059r3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41591-020-0803-x","article-title":"Joint international consensus statement for ending stigma of obesity.","volume":"26","author":"Rubino","year":"2020","journal-title":"Nat Med"},{"issue":"9","key":"soi250059r4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/obr.12889","article-title":"Management of overweight and obesity in primary care-A systematic overview of international evidence-based guidelines.","volume":"20","author":"Semlitsch","year":"2019","journal-title":"Obes Rev"},{"issue":"4","key":"soi250059r5","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400229","article-title":"Associations between class I, II, or III obesity and health outcomes.","volume":"4","author":"Yao","year":"2025","journal-title":"NEJM Evid"},{"issue":"3","key":"soi250059r6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.18553\/jmcp.2021.20410","article-title":"Direct medical costs of obesity in the United States and the most populous states.","volume":"27","author":"Cawley","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"soi250059r7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41366-023-01398-y","article-title":"Economic costs of obesity: a systematic review.","volume":"48","author":"Nagi","year":"2024","journal-title":"Int J Obes (Lond)"},{"issue":"9","key":"soi250059r8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2022-009773","article-title":"Economic impacts of overweight and obesity: current and future estimates for 161 countries.","volume":"7","author":"Okunogbe","year":"2022","journal-title":"BMJ Glob Health"},{"issue":"4","key":"soi250059r9","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/ijerph14040435","article-title":"Economic burden of obesity: a systematic literature review.","volume":"14","author":"Tremmel","year":"2017","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"soi250059r10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1001\/jama.2014.16968","article-title":"Association between bariatric surgery and long-term survival.","volume":"313","author":"Arterburn","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"soi250059r11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/SLA.0000000000005003","article-title":"Patient-reported outcomes after metabolic surgery versus medical therapy for diabetes: insights from the STAMPEDE randomized trial.","volume":"274","author":"Aminian","year":"2021","journal-title":"Ann Surg"},{"issue":"9997","key":"soi250059r12","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/S0140-6736(15)00075-6","article-title":"Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial.","volume":"386","author":"Mingrone","year":"2015","journal-title":"Lancet"},{"issue":"7","key":"soi250059r13","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes\u20145-year outcomes.","volume":"376","author":"Schauer","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"soi250059r14","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s11695-018-3501-8","article-title":"Cancer risk following bariatric surgery-systematic review and meta-analysis of national population-based cohort studies.","volume":"29","author":"Wiggins","year":"2019","journal-title":"Obes Surg"},{"issue":"15","key":"soi250059r15","first-page":"S288","article-title":"A review of current guidelines for the treatment of obesity.","volume":"28","author":"Cornier","year":"2022","journal-title":"Am J Manag Care"},{"issue":"3","key":"soi250059r16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1161\/HYPERTENSIONAHA.118.12290","article-title":"Effects of bariatric surgery versus medical therapy on the 24-hour ambulatory blood pressure and the prevalence of resistant hypertension.","volume":"73","author":"Schiavon","year":"2019","journal-title":"Hypertension"},{"issue":"8","key":"soi250059r17","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1007\/s11695-021-05455-1","article-title":"Long-term results of one anastomosis gastric bypass: a single center experience with a minimum follow-up of 10 years.","volume":"31","author":"Carandina","year":"2021","journal-title":"Obes Surg"},{"issue":"10271","key":"soi250059r18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(20)32649-0","article-title":"Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial.","volume":"397","author":"Mingrone","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"soi250059r19","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.1007\/s11695-021-05394-x","article-title":"What is weight loss after bariatric surgery expressed in percentage total weight loss (%TWL)? a systematic review.","volume":"31","author":"van Rijswijk","year":"2021","journal-title":"Obes Surg"},{"issue":"7","key":"soi250059r20","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.soard.2022.03.020","article-title":"Five-year weight loss, physical activity, and eating style trajectories after bariatric surgery.","volume":"18","author":"Voorwinde","year":"2022","journal-title":"Surg Obes Relat Dis"},{"issue":"2","key":"soi250059r21","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1007\/s11695-020-05037-7","article-title":"Early weight loss following laparoscopic sleeve gastrectomy is predictive of long-term weight loss in morbidly obese Chinese.","volume":"31","author":"Wang","year":"2021","journal-title":"Obes Surg"},{"key":"soi250059r22","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/dom.14235","article-title":"Metabolic surgery: a clinical update.","volume":"23","author":"Wilson","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"soi250059r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101882","article-title":"Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.","volume":"58","author":"Chakhtoura","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"1","key":"soi250059r25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial.","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"14","key":"soi250059r26","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial.","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"soi250059r27","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1002\/oby.23563","article-title":"Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: a systematic review and meta-analysis.","volume":"30","author":"Sarma","year":"2022","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"soi250059r28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.32614\/RJ-2017-037","article-title":"Furniture for quantitative scientists.","volume":"9","author":"Barrett","year":"2017","journal-title":"R J"},{"issue":"1","key":"soi250059r29","doi-asserted-by":"publisher","first-page":"570","DOI":"10.32614\/RJ-2021-053","article-title":"Reproducible summary tables with the gtsummary Package.","volume":"13","author":"Sjoberg","year":"2021","journal-title":"R J"},{"issue":"43","key":"soi250059r30","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse.","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"issue":"10","key":"soi250059r31","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"soi250059r32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-089477","article-title":"Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis.","volume":"15","author":"Squire","year":"2025","journal-title":"BMJ Open"},{"issue":"11","key":"soi250059r33","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.1111\/dom.15911","article-title":"Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: an analysis of the All of US Program.","volume":"26","author":"Mayer","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"34","key":"soi250059r34","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e213","article-title":"Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records.","volume":"33","author":"Kim","year":"2018","journal-title":"J Korean Med Sci"},{"issue":"8","key":"soi250059r35","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2217\/fon-2020-0951","article-title":"Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer.","volume":"17","author":"Nazha","year":"2021","journal-title":"Future Oncol"},{"issue":"5","key":"soi250059r36","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/oby.24002","article-title":"Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis.","volume":"32","author":"Pan","year":"2024","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"soi250059r37","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials.","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"issue":"6","key":"soi250059r38","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"soi250059r39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity.","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"soi250059r40","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"soi250059r41","doi-asserted-by":"publisher","first-page":"860","DOI":"10.18553\/jmcp.2024.23332","article-title":"Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes.","volume":"30","author":"Gleason","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"soi250059r42","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae283","article-title":"International consensus position statement on the role of obesity management medications in the context of metabolic bariatric surgery: expert guideline by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO).","volume":"111","author":"Cohen","year":"2024","journal-title":"Br J Surg"},{"issue":"11","key":"soi250059r43","doi-asserted-by":"publisher","first-page":"6560","DOI":"10.1007\/s00464-024-11191-1","article-title":"A cost comparison of GLP-1 receptor agonists and bariatric surgery: what is the break even point?","volume":"38","author":"Docimo","year":"2024","journal-title":"Surg Endosc"},{"key":"soi250059r23","unstructured":"International Federation for the Surgery of Obesity Metabolic Disorders. 8th IFSO global registry report. Accessed March 7, 2024. https:\/\/www.ifso.com\/pdf\/8th-ifso-registry-report-2023.pdf"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2839126\/jamasurgery_barrett_2025_oi_250059_1762891101.16948.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T16:01:38Z","timestamp":1762963298000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2839126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2025.3590","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}